Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 23, 2010

TAP Negotiates Additional Distribution Rights to Aviso’s Automated Stem Cell Picker

  • The Automation Partnership negotiated distribution rights to Aviso’s CellCelector™ automated stem cell picker in the U.K. and Ireland. TAP will also continue to service the product in North America, under the terms of its previous distribution agreement, signed in January 2009, granting the firm marketing rights to CellCelector in the U.S. and Canada.

    Aviso claims the patented CellCelector allows the automated selection and harvesting of a variety of stem cell types. The firm describes the system as a freely configurable tool for the automated transfer of single cells and cell colonies.

    Aviso says that the CellCelector system is already used for a range of applications, ranging from the isolation and transfer of single cells and cell colonies from liquid, semisolid, or solid medium through to the isolation of cell material prepared from histological tissue sections.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »